Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis

Immunotherapy. 2020 Aug;12(12):857-860. doi: 10.2217/imt-2020-0094. Epub 2020 Jul 7.

Authors

Daniel Wendling¹, Philippe Goupille²

Affiliations

¹ Service de Rhumatologie, CHRU de Besançon EA 4266, Université de Franche-Comté, Besançon, France.
² Service de Rhumatologie, CHRU de Tours EA 7501, GICC, Université de Tours, Tours, France.

PMID: 32635788
DOI: 10.2217/imt-2020-0094

No abstract available

Keywords: ankylosing spondylitis; anti-IL-17; anti-TNF; axial spondyloarthritis; disease activity; treatment.

Publication types

Editorial

MeSH terms

Antirheumatic Agents / therapeutic use*
Biological Products / therapeutic use*
Humans
Patient Selection*
Spondylarthritis / drug therapy*

Substances

Antirheumatic Agents
Biological Products